Chemo-immunotherapy (CT-IT) currently represents the standard therapy for both non-small (NSCLC) and small cell lung cancer (SCLC). However, the differential impact of platinum compounds on immunotherapy outcomes remains to be determined.
Methods
A systematic review was conducted to identify randomized controlled trials (RCTs) of combinations of immune check-point inhibitors (ICIs) and platinum-based chemotherapy (CT), providing separate outcome data for carboplatin and cisplatin. Since no direct comparison between the two platinum compounds was reported, a network meta-analysis was performed. The primary endpoints were overall survival (OS) and progression-free survival (PFS) for advanced NSCLC and SCLC and event-free survival (EFS) for early-stage NSCLC.
Results
Eleven RCTs including 6125 patients were analyzed. In extensive-stage SCLC (four trials, 2663 patients), a non-significant trend toward improved OS was observed with cisplatin-based regimens (HR: 0.92, 95% CI 0.72–1.18; I2=47%). In advanced NSCLC (four trials, 1948 patients), a non-significant trend toward improved PFS was observed with carboplatin-based regimens (cisplatin vs carboplatin HR: 1.11, 95% CI 0.89–1.39; I2=0%). In early-stage NSCLC (three trials, 1514 patients), no differences emerged in EFS between subgroups (p=0.65 fixed-effect; p=0.49 random-effects).
Conclusions
Our analysis does not demonstrate a statistically significant difference between cisplatin- and carboplatin-based CT-IT in lung cancer, although stage- and histology-specific numerical trends were observed. Given the absence of head-to-head comparisons and the lack of disaggregated baseline data, these findings should be considered exploratory.
ZerAAhnMJBarlesiF, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol2025; 36(11):1245-1262
2.
HendriksL EKerrKMMenisJ, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol2023; 34: 358–376.
3.
DingemansA-MCFrühMArdizzoniL, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2021; 32: 839–853.
4.
ArdizzoniABoniLTiseoM, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst2007; 99: 847-857.
5.
RossiADi MaioMChiodiniP, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol2012; 30: 1692-1698.
6.
GriesingerFKorolEEKayaniyilS, et al. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer2019; 135: 196-204.
7.
JiangSHuangLZhenH, et al. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. BMC Cancer2021; 21: 1308.
8.
GandhiLRodríguez-AbreuDGadgeelS, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med2018; 378: 2078-2092.
9.
HornLMansfieldASSzczęsnaA, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med2018; 379: 2220-2229.
10.
SpicerJDCasconeTWynesMW, et al. Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the International Association for the Study of Lung Cancer. J Thorac Oncol2024; 19: 1373-1414.
PageMJMoherDBossuytPM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ2021; 372: n160.
13.
SterneJACSavovićJPageMJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019; 366: l4898.
14.
HigginsJPTThomasJChandlerJ, et al (eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024.
15.
Rayyan Systems Inc. Rayyan Intelligent Systematic Review. 2023. Available at: https://www.rayyan.ai/ (accessed 4 September 2025).
16.
RückerG. Network meta-analysis, electrical networks and graph theory. Res Synth Method2012; 3: 312-324.
17.
HuttonBSalantiGCaldwellDM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med2015; 162: 777-784.
18.
ReckMLuftASzczesnaA, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol2016; 34: 3740-3748.
19.
RudinCMAwadMMNavarroA, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol2020; 38: 2369-2379.
20.
Paz-AresLChenYReinmuthN, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open2022; 7: 100408.
21.
ChengYFanYZhaoY, et al. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): A multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol2024; 19: 1073-1085.
22.
YangYWangZFangJ, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol2020; 15: 1636-1646.
23.
NishioMBarlesiFWestH, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 Trial. J Thorac Oncol2021; 16: 653-664.
24.
Rodríguez-AbreuDPowellSFHochmairMJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol2021; 32: 881-895.
25.
ZhouCWuLFanY, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). J Thorac Oncol2021; 16: 1501-1511.
26.
FordePMSpicerJLuS, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med2022; 386: 1973-1985.
27.
HeymachJVHarpoleDMitsudomiT, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med2023; 389: 1672-1684.
28.
CasconeTAwadMMSpicerJD, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med2024; 390: 1756-1769.
29.
SorinMProstyCGhalebL, et al. Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis. JAMA Oncol2024; 10: 621-633.
30.
De MarinisFGebbiaVDe PetrisL. Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer. Ann Oncol2005; 16 Suppl 4: iv116-122.
31.
PignonJPTribodetHScagliottiGV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol2008; 26: 3552-3559.
32.
StraussGMHerndonJE2ndMaddausMA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol2008; 26: 5043-5051.
33.
RosellRGatzemeierUBetticherDC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol2002; 13: 1539-1549.
34.
VasconcellosVFMartaGNda SilvaEM, et al. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev2020; 1: CD009256.
35.
AzarIYazdanpanahOJangH, et al. Comparison of carboplatin with cisplatin in small cell lung cancer in US veterans. JAMA Netw Open2022; 5: e2237699.
36.
SamaSKerriganKSinnottJA, et al. Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer. Cancer Treat Res Commun2023; 35: 100686.
37.
LazzariCKarachaliouNBulottaA, et al. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?Ther Adv Med Oncol2018; 10:1758835918762094.
38.
LeonettiAFacchinettiFMinariR, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Update2019; 46: 100644.
39.
HatoSVKhongAde VriesIJM, et al. Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res2014; 20: 2831–2837.
40.
FournelLWuZStadlerN, et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett2019; 464: 5–14.
41.
GalskyMDGuanXRishipathakD, et al. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. Cell Rep Med2024; 5: 101393.
42.
de BiasiARVillena-VargasJAdusumilliPS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res2014; 20: 5384-5391.
43.
BeheraRZhuJGiudiceGC, et al. 486 Cisplatin vs carboplatin-based chemotherapy combined with immune checkpoint inhibitor (ICI)- meta-analysis of efficacy and toxicities in randomized clinical trials.J Immunother Cancer2024; 12(Suppl 2): A548.
44.
MoriKPradereBQuhalF, et al. Reassessment of the efficacy of carboplatin for metastatic urothelial carcinoma in the era of immunotherapy: a systematic review and meta-analysis. Eur Urol Focus2022; 8: 1687–1695.
45.
BolekHYazganSCYekedüzE, et al. Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma. Oncologist2024; 29: 999–1002.
46.
CiccoliniJSerdjebiCPetersGJ, et al. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol2016; 78: 1–12.
47.
MathewMEnzlerTShuCA, et al. Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacol Ther2018; 186: 130–137.
48.
ZitvogelLApetohLGhiringhelliF, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol2008; 8: 59–73.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
